4-fluoro-piperidine T-type calcium channel antagonists

Details for Australian Patent Application No. 2006263564 (hide)

Owner Merck & Co., Inc.

Inventors Shipe, William D.; Yang, Zhiqiang; Barrow, James C.; Wisnoski, David; Lindsley, Craig W.

Agent Spruson & Ferguson

Pub. Number AU-A-2006263564

PCT Pub. Number WO2007/002884

Priority 60/695,073 29.06.05 US

Filing date 28 June 2006

Wipo publication date 4 January 2007

International Classifications

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

C07D 211/00 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 295/00 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Event Publications

10 January 2008 PCT application entered the National Phase

  PCT publication WO2007/002884 Priority application(s): WO2007/002884

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006263566-Compositions and methods for less immunogenic protein-lip1d complexes

2006263563-Products containing polyphenols